Invention Grant
- Patent Title: Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
-
Application No.: US15777102Application Date: 2016-11-17
-
Publication No.: US11213539B2Publication Date: 2022-01-04
- Inventor: Philippe Martel , Nabil Kerrouche , Fabien Audibert
- Applicant: GALDERMA HOLDING SA
- Applicant Address: FR La Tour-de-Peilz
- Assignee: GALDERMA HOLDING SA
- Current Assignee: GALDERMA HOLDING SA
- Current Assignee Address: FR La Tour-de-Peilz
- Agency: Foley & Lardner LLP
- Agent Sunil Talapatra
- Priority: EP15306822 20151117
- International Application: PCT/EP2016/078076 WO 20161117
- International Announcement: WO2017/085226 WO 20170526
- Main IPC: A61K31/7048
- IPC: A61K31/7048 ; A61K31/498 ; A61P17/00
Abstract:
The present invention relates to a combination of ivermectin and brimonidine for use in the treatment and/or the prevention of moderate to severe rosacea, preferably by topical administration of a 1% ivermectin cream and 0.33% brimonidine gel.
Public/Granted literature
- US20180344757A1 USE OF IVERMECTIN AND BRIMONIDINE IN THE TREATMENT AND/OR PREVENTION OF MODERATE TO SEVERE ROSACEA Public/Granted day:2018-12-06
Information query
